Skip to main content

The current clinical value of the DCIS Score.

Publication ,  Conference
Wood, WC; Alvarado, M; Buchholz, DJ; Hyams, D; Hwang, S; Manders, J; Park, C; Solin, LJ; White, J; Willey, S
Published in: Oncology (Williston Park)
May 2014

The management of ductal carcinoma in situ (DCIS) can be controversial. Widespread adoption of mammographic screening has made DCIS a more frequent diagnosis, and increasingly smaller, lower-grade lesions are being detected. DCIS is commonly treated with breast-conserving surgery and radiation. However, there is greater recognition that acceptable cancer control outcomes can be achieved for some patients with breast-conserving surgery alone, with radiotherapy reserved for those at higher risk of in-breast recurrence. The primary clinical dilemma is that there are currently no reliable clinicopathologic features that accurately predict which patients will have a recurrence, but risk stratification is an area of active research. Molecular profiling has the potential to assess recurrence risk based on the individual patient's tumor biology and guide treatment decisions. The DCIS Score is a 12-gene assay intended to support personalized treatment planning for patients with DCIS following local excision. It provides information on local failure risk independent of traditional clinicopathologic features. Our group of expert breast surgeons and radiation oncologists met in December 2013 at the San Antonio Breast Cancer Symposium to discuss current controversies in DCIS management and determine the potential value of the DCIS Score in managing these situations. We concluded that the DCIS Score provides clinically relevant information about personal risk that can guide patient discussions and facilitate shared decision making.

Duke Scholars

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

May 2014

Volume

28 Suppl 2

Start / End Page

C2 / C3

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Radiotherapy, Adjuvant
  • Predictive Value of Tests
  • Precision Medicine
  • Phenotype
  • Patient Selection
  • Neoplasm Recurrence, Local
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wood, W. C., Alvarado, M., Buchholz, D. J., Hyams, D., Hwang, S., Manders, J., … Willey, S. (2014). The current clinical value of the DCIS Score. In Oncology (Williston Park) (Vol. 28 Suppl 2, pp. C2–C3). United States.
Wood, William C., Michael Alvarado, Daniel J. Buchholz, David Hyams, Shelley Hwang, Jennifer Manders, Catherine Park, Lawrence J. Solin, Julia White, and Shawna Willey. “The current clinical value of the DCIS Score.” In Oncology (Williston Park), 28 Suppl 2:C2–3, 2014.
Wood WC, Alvarado M, Buchholz DJ, Hyams D, Hwang S, Manders J, et al. The current clinical value of the DCIS Score. In: Oncology (Williston Park). 2014. p. C2–3.
Wood, William C., et al. “The current clinical value of the DCIS Score.Oncology (Williston Park), vol. 28 Suppl 2, 2014, pp. C2–3.
Wood WC, Alvarado M, Buchholz DJ, Hyams D, Hwang S, Manders J, Park C, Solin LJ, White J, Willey S. The current clinical value of the DCIS Score. Oncology (Williston Park). 2014. p. C2–C3.

Published In

Oncology (Williston Park)

ISSN

0890-9091

Publication Date

May 2014

Volume

28 Suppl 2

Start / End Page

C2 / C3

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Radiotherapy, Adjuvant
  • Predictive Value of Tests
  • Precision Medicine
  • Phenotype
  • Patient Selection
  • Neoplasm Recurrence, Local